about
Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjectsDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyUtility of an Algorithm to Increase the Accuracy of Medication History in an Obstetrical SettingDevelopment and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapyPopulation pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.Tobramycin exposure from active calcium sulfate bone graft substitutePopulation pharmacokinetics of atazanavir in patients with human immunodeficiency virus infectionPopulation pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsPharmacokinetic-pharmacodynamic modelling: history and perspectives.Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignanciesPopulation pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovirPopulation pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Benchmarking therapeutic drug monitoring software: a review of available computer tools.Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes.Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.Therapeutic drug monitoring of targeted anticancer therapy.Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients.Pharmacometrics-based decision tools facilitate mHealth implementation.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine exposure.Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry.
P50
Q24678803-2EFAE055-CB87-42C5-8E31-D7350DA144B6Q28478666-098A8837-DEC3-4957-AE44-C853CA21D5ACQ28550918-833A315B-9DF8-4761-A534-225134024C37Q33873614-55C94EDD-8BBD-49EC-914D-EF0462C6EA37Q34058351-F19E1D53-9D79-4E9D-9411-1F302D3A9E15Q34209573-4E6C1F8B-D78A-4AAA-AE68-02089DF23253Q34570930-D77F754C-9B48-4DD9-BF54-C0C49681D9ECQ35110405-8C7A2CC3-16E0-471B-8CD2-9BF5791A8357Q35127808-977121CD-4DDD-417C-AE66-D58DD1884E65Q35827616-38930B0C-7474-47DC-905D-EC10F6208181Q36018556-468ACB5D-3417-4394-B2B2-ACD196A3FB15Q36365141-7730BC46-063D-4305-AA53-5524FFCCEF41Q36558437-76C52D3C-54C2-41E5-94AA-7AB6DE67D575Q36592753-764445A0-5847-4D86-BFC0-1FBC7D186D4BQ36667469-F5DA0516-019C-4491-AFD3-395D4FBD0B79Q36729934-C354EF12-7A53-4F30-B149-2A8DC3E6BCB2Q36845126-B4D7B1BF-BD35-4A9D-BAE5-0A005BB11727Q36969893-E8F05431-FA22-4DEC-B0F8-5C386ED97F13Q37038270-828612C6-7A34-47AB-BF4B-E802C2E28C29Q37072039-D04B0EF3-D449-495B-B0E4-4F05AE053E35Q37247594-69B9FA59-0CC0-4FA3-A13B-96619AC35605Q37489345-DA95A02F-DB71-419E-8C41-0E6D5BCAC959Q37538683-88556E64-85DE-4A13-9C9A-0AD425225DCDQ37866298-2F40653A-FE85-4452-A7B2-439D0ED51FE5Q38063750-6C541D1C-4534-4E22-932F-6833FF9B2610Q38090431-1A835761-98F0-481F-B542-4AFB41C231D8Q38305749-5CA4B315-5475-438D-B764-BBCA716ACA60Q38579278-4FA31F4A-B739-464E-8AF6-D38BBC90B5EBQ38696468-0B16682A-06BD-42FE-AEBA-1D732FE0BA56Q38760587-80A42248-443C-43C2-814D-73AA30BA97CFQ38998626-EB64F1B1-55C1-40ED-92D5-04EF0E4DB9BAQ39116591-1EBE54B2-D9C5-43AA-94ED-3A6064B2BF21Q39651800-7F97C0EF-BE6E-4F17-B28B-2CF77A6383ACQ39756442-1875B287-A2F3-4713-9F99-11F0B456E96DQ39951476-DE8D1673-9555-4006-B694-B9BA4DFD7C9EQ40735151-9641DA3C-033E-480F-A4EF-C66E896CFEDFQ40780592-728A4AC9-1D8C-4353-AE53-6A8527543CAFQ41333137-59C13DAE-F947-4D24-AA6F-30CD936AA7F1Q41639978-164DB392-88AE-4052-8F36-72E907D682A5Q42205826-B2E1E2F4-E74C-4E0E-95C5-82929E083409
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chantal Csajka
@ast
Chantal Csajka
@en
Chantal Csajka
@es
Chantal Csajka
@nl
Chantal Csajka
@sl
type
label
Chantal Csajka
@ast
Chantal Csajka
@en
Chantal Csajka
@es
Chantal Csajka
@nl
Chantal Csajka
@sl
prefLabel
Chantal Csajka
@ast
Chantal Csajka
@en
Chantal Csajka
@es
Chantal Csajka
@nl
Chantal Csajka
@sl
P106
P1153
15051589500
P21
P31
P496
0000-0002-0660-082X